Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Plasticity of Lineage and Immune Evasion in Primary SCLC and Transformation from LUAD to SCLC: Loss of Antigen Presentation and Shifts in Therapeutic Strategies

  • By

  • Hongying Xu

  • Benhua Li

  • Jun Yang

  • Xin Tang

  • September 4, 2026

Share

  • 1

    Lineage plasticity in SCLC contributes to immune resistance by impairing MHC-I antigen processing and presentation.

  • 2

    Neuroendocrine differentiation is linked to reduced antigen presentation in primary SCLC and experimental models.

  • 3

    Transformation from EGFR-mutant LUAD to SCLC may involve similar alterations in antigen presentation, though not yet confirmed.

  • 4

    Current immunotherapy strategies have shown limited durable benefits in SCLC, particularly in transformed cases.

  • 5

    Antigen presentation capacity is crucial for immune checkpoint blockade efficacy in SCLC, influencing treatment outcomes.

Original Source(s)

Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection

  • by Hongying Xu, Benhua Li, Jun Yang, Xin Tang

  • September 4, 2026

Related Content

Toward Precision Cardio-Oncology in Breast Radiotherapy

Therapy-induced immunoediting and the evolution of cancer immune escape

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min